We anticipate that CNT-based biosensors will ultimately provide a rapid clinical tool to accurately and inexpensively help define the therapeutic potential of candidate biomarkers, such as IGF-1 for the early detection of breast cancer. This evidence concerns the gene IGF1 and breast carcinoma.